Novogen, an Australian biotech with an office in New Haven, said it will work with researchers at Cornell University to develop its treatment aimed at long-term remission of the most common type of brain cancer.
The research program will focus on getting Novogen’s drug Trilexium into the clinic to test it as a treatment for glioblastoma multiforme (GBM) that is not responding to Temozolomide.
GBM is the most common and aggressive form of brain cancer.
Novogen said the program with Cornell parallels its joint venture with Yale, called CanTx. The venture is focused on ovarian cancer.
